Abstract
Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by chronic respiratory tract infections and in some cases laterality defects and infertility. The symptoms of PCD are caused by malfunction of motile cilia, hair-like organelles protruding out of the cell that are responsible for removal of mucus from the airways, organizing internal organ positioning during embryonic development and gamete transport. PCD is caused by mutations in genes coding for structural or assembly proteins of motile cilia. Thus far, mutations in over 50 genes have been identified and these variants explain around 70% of all known cases. Population specific genetics underlying PCD has been reported underlining the importance of characterizing gene variants in different populations for development of gene-based diagnostics and management. In this study, we identified disease causing genetic variants in the axonemal central pair component HYDIN. Three Finnish PCD patients carried homozygous loss-of-function variants and one patient had compound heterozygous variants within the HYDIN gene. The functional effect of the HYDIN variants was confirmed by immunofluorescence and electron tomography, which demonstrated defects in the axonemal central pair complex. All patients had clinical PCD symptoms including chronic wet cough and recurrent airway infections due to almost static airway cilia. Our results are consistent with the previously identified important role of HYDIN in the axonemal central pair complex and improve specific diagnostics of PCD in different ethnical backgrounds.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
BBSRC grant BB/V011251/1, Marie Sklodowska-Curie individual fellowship No. 800556 from the European Unions Horizon 2020 Research and Innovation Programme, NIHR GOSH BRC, Ministry of Higher Education in Egypt, the BEAT-PCD network (COST Action 1407 and European Respiratory Society (ERS) Clinical Research Collaboration) and a Wellcome Trust Collaborative Award in Science (210585/Z/18/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was ethically approved by the University of Turku Ethics Committee (ETMK 69 2017), London Bloomsbury Research Ethics Committee approved by the Health Research Authority (08/H0713/82), and the referring hospitals.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
